284 related articles for article (PubMed ID: 30100404)
1. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial.
Raghu G; Pellegrini CA; Yow E; Flaherty KR; Meyer K; Noth I; Scholand MB; Cello J; Ho LA; Pipavath S; Lee JS; Lin J; Maloney J; Martinez FJ; Morrow E; Patti MG; Rogers S; Wolters PJ; Yates R; Anstrom KJ; Collard HR
Lancet Respir Med; 2018 Sep; 6(9):707-714. PubMed ID: 30100404
[TBL] [Abstract][Full Text] [Related]
2. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
3. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre.
Raghu G; Morrow E; Collins BF; Ho LA; Hinojosa MW; Hayes JM; Spada CA; Oelschlager B; Li C; Yow E; Anstrom KJ; Mart D; Xiao K; Pellegrini CA
Eur Respir J; 2016 Sep; 48(3):826-32. PubMed ID: 27492835
[TBL] [Abstract][Full Text] [Related]
4. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.
Lee JS; Collard HR; Anstrom KJ; Martinez FJ; Noth I; Roberts RS; Yow E; Raghu G;
Lancet Respir Med; 2013 Jul; 1(5):369-76. PubMed ID: 24429201
[TBL] [Abstract][Full Text] [Related]
5. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
[TBL] [Abstract][Full Text] [Related]
7. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Kreuter M; Wuyts W; Renzoni E; Koschel D; Maher TM; Kolb M; Weycker D; Spagnolo P; Kirchgaessler KU; Herth FJ; Costabel U
Lancet Respir Med; 2016 May; 4(5):381-9. PubMed ID: 27050871
[TBL] [Abstract][Full Text] [Related]
8. Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Khor YH; Bissell B; Ghazipura M; Herman D; Hon SM; Hossain T; Kheir F; Knight SL; Kreuter M; Macrea M; J Mammen M; Molina-Molina M; Selman M; Wijsenbeek M; Raghu G; Wilson KC
Ann Am Thorac Soc; 2022 May; 19(5):833-844. PubMed ID: 35486080
[No Abstract] [Full Text] [Related]
9. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
[TBL] [Abstract][Full Text] [Related]
10. Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance.
Hoppo T; Komatsu Y; Jobe BA
Dis Esophagus; 2014 Aug; 27(6):530-7. PubMed ID: 23107023
[TBL] [Abstract][Full Text] [Related]
11. Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone.
Kreuter M; Spagnolo P; Wuyts W; Renzoni E; Koschel D; Bonella F; Maher TM; Kolb M; Weycker D; Kirchgässler KU; Costabel U
Respiration; 2017; 93(6):415-423. PubMed ID: 28399537
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial.
Raghu G; Brown KK; Collard HR; Cottin V; Gibson KF; Kaner RJ; Lederer DJ; Martinez FJ; Noble PW; Song JW; Wells AU; Whelan TP; Wuyts W; Moreau E; Patterson SD; Smith V; Bayly S; Chien JW; Gong Q; Zhang JJ; O'Riordan TG
Lancet Respir Med; 2017 Jan; 5(1):22-32. PubMed ID: 27939076
[TBL] [Abstract][Full Text] [Related]
13. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Moran D; Santin-Janin H; Aubin F; Mulder GJ; Gupta R; Richeldi L
Lancet Respir Med; 2019 Aug; 7(8):657-664. PubMed ID: 31122893
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis.
Raghu G; Freudenberger TD; Yang S; Curtis JR; Spada C; Hayes J; Sillery JK; Pope CE; Pellegrini CA
Eur Respir J; 2006 Jan; 27(1):136-42. PubMed ID: 16387946
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Fidler L; Sitzer N; Shapera S; Shah PS
Chest; 2018 Jun; 153(6):1405-1415. PubMed ID: 29559309
[TBL] [Abstract][Full Text] [Related]
17. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
Richeldi L; Fernández Pérez ER; Costabel U; Albera C; Lederer DJ; Flaherty KR; Ettinger N; Perez R; Scholand MB; Goldin J; Peony Yu KH; Neff T; Porter S; Zhong M; Gorina E; Kouchakji E; Raghu G
Lancet Respir Med; 2020 Jan; 8(1):25-33. PubMed ID: 31575509
[TBL] [Abstract][Full Text] [Related]
18. Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.
Wu Z; Spencer LG; Banya W; Westoby J; Tudor VA; Rivera-Ortega P; Chaudhuri N; Jakupovic I; Patel B; Thillai M; West A; Wijsenbeek M; Maher TM; Smith JA; Molyneaux PL
Lancet Respir Med; 2024 Apr; 12(4):273-280. PubMed ID: 38237620
[TBL] [Abstract][Full Text] [Related]
19. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Paterniti MO; Bi Y; Rekić D; Wang Y; Karimi-Shah BA; Chowdhury BA
Ann Am Thorac Soc; 2017 Sep; 14(9):1395-1402. PubMed ID: 28388260
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
